Kura Oncology, Inc.
- KURA
- NASDAQ
- Biotechnology
- Oncology Drugs
- Menin Inhibitor
- Clinical-Stage Biotech
$9.73
Today +3.95%Quote Oct 20, 2026, 02:09 PM UTC
−20.20%over the last month
Max drawdown −22.6%From 1-month high −20.2%3 months −14.0%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Kura Oncology
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer.
Where the money comes from
Q2 2026 revenue $20.9M
- Collaboration Revenue$11.8M56.3%
- Product$9.1M43.7%
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
260
Market value
$865.6M
Quote Oct 20
Analyst target
$24.00
+146.7% from here
Floor
$9.60
1.3% below price
Resistance
$10.16
4.4% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about KURAPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free